Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on July 9, 2026

Jul. 9, 2026

Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease

Indeterminate GlobeNewswire

Jul. 9, 2026

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Indeterminate GlobeNewswire

Jul. 9, 2026

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Indeterminate GlobeNewswire

Jul. 9, 2026

Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine

Indeterminate GlobeNewswire

Jul. 9, 2026

Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care

Indeterminate GlobeNewswire

Jul. 9, 2026

What Clinicians Ask About Cartilage Regeneration Supplements: Answering the Clinical Questions Around Cartigenix HP®

Indeterminate GlobeNewswire

Jul. 9, 2026

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

Indeterminate GlobeNewswire

Jul. 9, 2026

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Indeterminate GlobeNewswire

Jul. 9, 2026

NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner

Indeterminate GlobeNewswire

Jul. 9, 2026

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Indeterminate GlobeNewswire

Jul. 9, 2026

Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges

Indeterminate GlobeNewswire

Jul. 9, 2026

Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.

Indeterminate GlobeNewswire

Jul. 9, 2026

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Indeterminate GlobeNewswire